Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights ...

According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...

The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...

AstraZeneca’s targeted drug Tagrisso is a go-to for treating non-small cell lung cancer (NSCLC) patients whose tumors harbor mutations in the gene EGFR. But patients invariably become resistant to the ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Please provide your email address to receive an email when new articles are posted on . Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with ...

Roman Perez-Soler, M.D. discusses the EGFR resistance in non-small cell lung cancer (NSCLC). There may be some good news on the horizon for patients with non-small cell lung cancer (NSCLC) who are ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...